Idrotens (Hydrochlorothiazide, Candesartan Cilexetil)

Idrotens is an oral antihypertensive that targets the renin‑angiotensin system and renal sodium reabsorption to lower blood pressure.

• Essential hypertension: reduces systolic and diastolic pressure and lowers cardiovascular risk.
• Secondary hypertension: assists in blood‑pressure control when underlying causes are present.
• Hypertension with fluid retention: provides both vasodilation and diuretic action to manage excess fluid.

• Candesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. The combined actions result in reduced peripheral resistance and lowered blood pressure.

Common Side Effects

• Dizziness or light‑headedness.
• Increased urination.
• Headache.
• Fatigue.
• Electrolyte disturbances such as low potassium.
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis, rash, swelling).
• Significant electrolyte imbalance (hyperkalemia, hyponatremia).
• Acute kidney injury or worsening renal function.
• Angioedema affecting face, lips, or airway.
• Pancreatitis.
• Liver enzyme elevation.

Before initiating therapy, clinicians should assess renal function, electrolyte status, and potential drug interactions.

• Monitor electrolytes: check potassium and sodium levels regularly.
• Assess renal function: evaluate creatinine and eGFR before and during treatment.
• Use caution in elderly patients: increased sensitivity to blood‑pressure changes.
• Avoid concurrent use with other potassium‑sparing agents without monitoring.
• Review hepatic impairment: adjust if severe liver disease is present.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Idrotens may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid)

• Aliskiren: combined renin‑angiotensin blockade can increase risk of renal impairment.
• Potassium supplements or high‑potassium diet: may cause hyperkalemia.
• Lithium: increased lithium levels and toxicity risk.
• NSAIDs: may reduce antihypertensive efficacy and affect renal function.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or other ARBs: additive blood‑pressure lowering effect; monitor for hypotension.
• Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustment.
• Diuretics (loop or potassium‑sparing): monitor electrolytes and renal function.
• CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase candesartan plasma concentrations.